Psilocybin is being investigated for persistent pain, including fibromyalgia and phantom limb pain. Early findings suggest that some people may experience changes in pain, sleep or the degree to which symptoms dominate daily life. Whether these changes represent a reliable treatment effect, how long they last and which patients might benefit remain unresolved.
A person may become more active or less distressed while pain intensity changes little. Pain may also diminish without restoring sleep, mobility or work. Each outcome matters, and each needs to be assessed separately.
On this page
- Persistent pain is a real clinical experience
- Different pain mechanisms cannot be treated as interchangeable
- What the fibromyalgia pilot found
- Phantom limb pain and other chronic pain conditions
- Possible mechanisms and their limits
- Safety in people who already take several medicines
- Continuing care and realistic treatment goals
Persistent pain is a real clinical experience
Pain involves sensory and emotional experience, influenced by biological, psychological and social factors. The involvement of attention, expectation or emotion does not make pain imaginary. Nor does a normal investigation prove that symptoms are trivial. Assessment should respect the person’s report while considering the possible causes and consequences of pain.1
“A person’s report of an experience as pain should be respected.”
International Association for the Study of Pain, notes accompanying its revised pain definition.1
The distinction between pain and tissue damage is relevant to psychedelic claims. If an intervention changes pain, this does not establish that damaged tissue has healed. Conversely, improvement through psychological treatment does not show that there was never a biological problem. Clinical interpretation depends on the condition being treated and on what has actually changed.
Different pain mechanisms cannot be treated as interchangeable
Nociceptive pain arises in relation to actual or threatened damage to non-neural tissue. Neuropathic pain involves a lesion or disease of the somatosensory nervous system. Nociplastic pain describes altered nociception when there is no clear evidence that tissue damage or a somatosensory lesion adequately accounts for it. More than one mechanism can contribute to a person’s symptoms.2
Fibromyalgia commonly involves widespread pain, fatigue, disturbed sleep and difficulties with concentration. It is associated with altered pain processing, but patients can also have other painful conditions. New symptoms still require assessment. The diagnosis is clinical rather than the result of a single definitive blood test or scan.34
| Outcome | What it describes | What it cannot establish alone |
|---|---|---|
| Pain intensity | How severe pain feels over a specified period | Improved mobility, sleep or tissue recovery |
| Pain interference | How much symptoms disrupt activity and participation | That the pain has disappeared |
| Sleep and fatigue | Rest, energy and ability to sustain activity | A direct analgesic mechanism |
| Mood and distress | Depression, anxiety or suffering associated with pain | That the original pain was caused by a mood disorder |
| Medication use | Changes in prescribed or rescue treatment | Safer care unless withdrawal, symptoms and function are also assessed |
What the fibromyalgia pilot found
The first published open-label fibromyalgia pilot treated five women with two psilocybin sessions, preparation and subsequent integration appointments. Its main purpose was to examine safety and feasibility. One month after the second session, average pain severity had fallen by 2.3 points on a 0–10 scale. Three participants had a decrease exceeding two points. Pain interference and sleep scores also improved on average.5
The participants’ own overall assessments varied: one reported being very much improved, two much improved and two minimally improved. This variation matters. An average benefit should not be presented as the likely experience of every patient. The study did not show substantial average improvement in depressive symptoms, but the small sample cannot settle whether mood, expectation, altered pain processing or other factors contributed to the changes.5
There was no comparison group. It is therefore impossible to separate the effects of psilocybin from preparation, therapeutic attention, changes in behaviour, expectation or the natural course of symptoms. All five participants were women, and the selection criteria excluded frequent opioid use. These findings cannot establish efficacy in a broader fibromyalgia population or support a claim that psilocybin reduces opioid requirements.5
Transient cardiovascular changes occurred during treatment, and four participants reported headache. No serious adverse events were reported. With five people, this is a limited observation about a supervised intervention, not evidence that uncommon harms have been ruled out. A small safety pilot can identify practical problems while remaining unable to estimate rare or delayed adverse outcomes.5
Phantom limb pain and other chronic pain conditions
A 2026 randomised pilot in phantom limb pain enrolled nine participants: five received psilocybin and four received niacin as an active placebo. The study principally assessed feasibility and tolerability. There were no serious adverse events or emerging suicidality; transient discomfort and cardiovascular changes resolved before discharge. Exploratory pain ratings suggested improvement after psilocybin, but the tiny groups and difficulty maintaining blinding prevent a reliable efficacy conclusion. These are preliminary tolerability findings, not a demonstrated treatment for phantom limb pain.6
Results in fibromyalgia cannot be assumed to apply to arthritis, diabetic neuropathy, cancer pain, postoperative pain or every form of back pain. These conditions can differ in mechanism, medical urgency and available treatment. The wider psychedelic pain literature includes small trials, observational reports and individual cases, with considerable variation in diagnosis and intervention. The clinical question remains condition-specific.7
A person who reports less suffering after a session may have had a meaningful benefit. That account does not identify which component of treatment caused the change, establish an appropriate treatment schedule or tell another patient how likely they are to benefit. Such accounts are best treated as reasons to investigate particular outcomes more rigorously.
Possible mechanisms and their limits
Psilocin acts on serotonin receptors and can change perception, emotion and the interpretation of bodily sensations. Proposed pain mechanisms include changes in sensory processing, attention, the emotional salience of symptoms and behavioural flexibility. Laboratory findings about neural plasticity provide hypotheses, but they do not establish repair of damaged nerves or a clinically meaningful analgesic effect in humans.897
Research protocols examining brain markers in fibromyalgia may help clarify these possibilities. A protocol, however, describes an intended investigation rather than a completed result. Imaging changes would still need to be linked to durable clinical outcomes before they could guide treatment selection or serve as reliable markers of recovery.10
Feeling less threatened by pain may support activity and improve quality of life. It does not establish that an underlying disease has resolved, or make later symptoms safe to ignore. Rehabilitation and medical reassessment remain relevant even after a powerful subjective improvement.
Safety in people who already take several medicines
Persistent pain often requires coordinated care across medical and psychological services. A psychedelic assessment therefore needs a complete medication history, including prescribed medicines, over-the-counter products and supplements. Interaction data are incomplete. Changes to antidepressants, analgesics or other long-term treatment require an individual clinical plan; abrupt discontinuation can create problems that are distinct from the original pain condition.1112
Psilocybin can cause nausea, anxiety, headache and transient blood-pressure elevation. An altered state may also make bodily sensations feel unfamiliar or more threatening. Screening, preparation, a suitable setting and staff able to respond to medical or psychological deterioration are part of the intervention studied in clinical research. Trial findings should not be transferred directly to unsupervised use.1314
Follow-up should include unwanted effects as well as hoped-for gains. A person who feels disappointed, more anxious or less able to function needs assessment rather than an explanation that the treatment has simply uncovered necessary suffering. Persistent deterioration is a clinical outcome, even when the treatment was intended to help.
Continuing care and realistic treatment goals
For chronic primary pain, NICE recommends assessment of the person’s circumstances and consideration of approaches such as adapted exercise programmes and appropriately delivered cognitive behavioural therapy or acceptance and commitment therapy. Primary and secondary pain can coexist, and treatment of an underlying disease still matters. Recommendations for one pain category should not be applied indiscriminately to every painful condition.12
Fibromyalgia care commonly combines education, individually adapted movement, attention to sleep, psychological approaches and selected medication. Progress may be gradual and uneven. Activity plans need to take symptoms and capacity into account; an emotionally significant session does not justify a sudden attempt to override physical limits. Goals such as preparing meals, maintaining relationships or returning to a valued activity can be clinically meaningful even before pain is substantially reduced.4
A convincing psilocybin treatment effect would require adequately powered controlled trials showing sustained benefit in defined conditions, alongside acceptable harms and treatment burden. Pain intensity, daily function, sleep, medication changes and adverse outcomes all deserve attention. At present, the evidence supports careful investigation rather than a general analgesic claim or a promise of recovery after one or two sessions.
References
- International Association for the Study of Pain. IASP Announces Revised Definition of Pain. 16 July 2020; accessed 11 October 2026.
- International Association for the Study of Pain. Terminology. Pain definitions; accessed 11 October 2026.
- National Institute of Arthritis and Musculoskeletal and Skin Diseases. Fibromyalgia. Health information; accessed 11 October 2026.
- National Institute of Arthritis and Musculoskeletal and Skin Diseases. Fibromyalgia: Diagnosis, Treatment, and Steps to Take. Reviewed May 2024; accessed 11 October 2026.
- Aday JS, McAfee J, Conroy DA, et al. Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial. Front Pain Res (Lausanne). 2025;6:1527783. doi:10.3389/fpain.2025.1527783.
- Dean JG, Hurwitz E, Furnish T, et al. Feasibility and Tolerability of Psilocybin for Phantom Limb Pain. J Pain. Published online 7 August 2026:106404. doi:10.1016/j.jpain.2026.106404.
- Robinson CL, Fonseca ACG, Diejomaoh EM, et al. Scoping Review: The Role of Psychedelics in the Management of Chronic Pain. J Pain Res. 2024;17:965-973. doi:10.2147/jpr.s439348.
- Nichols DE. Psychedelics. Pharmacol Rev. 2016;68:264–355. doi:10.1124/pr.115.011478.
- de Vos CMH, Mason NL, Kuypers KPC. Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. Front Psychiatry. 2021;12:724606. doi:10.3389/fpsyt.2021.724606.
- Bornemann J, Close JB, Ahmad K, et al. Study protocol for "Psilocybin in patients with fibromyalgia: brain biomarkers of action". Front Psychiatry. 2024;15:1320780. doi:10.3389/fpsyt.2024.1320780.
- Halman A, et al. Drug–drug interactions involving classic psychedelics: A systematic review. J Psychopharmacol. 2024. doi:10.1177/02698811231211219.
- National Institute for Health and Care Excellence. Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain (NG193). Recommendations; accessed 11 October 2026.
- Yerubandi A, et al. Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2024;7:e245960. doi:10.1001/jamanetworkopen.2024.5960.
- Johnson MW, Richards WA, Griffiths RR. Human Hallucinogen Research: Guidelines for Safety. J Psychopharmacol. 2008;22:603–620. doi:10.1177/0269881108093587.